BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2025 8:03:21 AM | Browse: 74 | Download: 179
 |
Received |
|
2025-05-12 02:38 |
|
Peer-Review Started |
|
2025-05-13 00:03 |
|
First Decision by Editorial Office Director |
|
2025-05-30 02:49 |
|
Return for Revision |
|
2025-05-30 02:49 |
|
Revised |
|
2025-06-23 00:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-26 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-26 08:49 |
|
Articles in Press |
|
2025-09-26 08:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-15 08:30 |
|
Publish the Manuscript Online |
|
2025-12-23 08:03 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Harry Economos and Richard J MacIsaac |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Richard J MacIsaac, Director, Professor, Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, 4th Floor, Daly Wing, 35 Victoria Parade, PO Box 2900, Fitzroy 3065, Victoria, Australia. r.macisaac@unimelb.edu.au |
| Key Words |
Semaglutide; Glucagon-like peptide-1 receptor agonist; Chronic kidney disease; Diabetes; Albuminuria |
| Core Tip |
In people with type 2 diabetes and chronic kidney disease, semaglutide, saves kidneys, hearts and lives. The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications are now being proposed as the fourth pillar of diabetic kidney disease therapy, along with renin-angiotensin-aldosterone system blocking agents, sodium glucose co-transporter-2 inhibitors, and finerenone. We await definitive evidence to support a kidney protective effect of GLP-1RAs outside of the setting of diabetes. |
| Publish Date |
2025-12-23 08:03 |
| Citation |
Economos H, MacIsaac RJ. Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease. World J Nephrol 2025; 14(4): 109457 |
| URL |
https://www.wjgnet.com/2220-6124/full/v14/i4/109457.htm |
| DOI |
https://dx.doi.org/10.5527/wjn.v14.i4.109457 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
